DataString Consulting Company Logo
DataString Consulting Company Logo
Prasugrel Hydrochloride Market
Home»Top Market Reports»Prasugrel Hydrochloride Market

Prasugrel Hydrochloride Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802141, Published - April 2025

Segmented in Application (Stroke Prevention, Post-Traumatic Injuries, Drug Combination Therapies, Others), End User (Hospitals, Outpatient Clinics, Home Healthcare, Others), Manufacturing Process, Distribution Channel, Regulations and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Prasugrel Hydrochloride Market Outlook

The market, for Prasugrel hydrochloride was estimated at $714.2 million in 2024; and it is anticipated to increase to $1.0 billion by 2030 with projections indicating a growth to around $1.3 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 5.9% over the forecast period. The significance of Prasugrel Hydrochloride in the global market can be attributed to several key drivers. Prevalence of conditions such as acute coronary syndrome and percutaneous coronary intervention procedures in patients with thrombotic events has stimulated demand for Prasugrel Hydrochloride. Ongoing advancements in cardiovascular treatment procedures further augments its relevance in the medical industry. The consistent need for effective anticoagulants ensures that Prasugrel Hydrochloride maintains a steady market position despite evolving treatment methodologies.


Prasugrel Hydrochloride is an antiplatelet medication that plays an essential role in preventing the formation of dangerous clots in blood vessels. Prized for its efficacy and safety, it is widely included in treatment protocols for complex cases involving cardiovascular complications. Recent years have seen a rise in different applications, underpinning new usage paradigms within myocardial infarction and stroke prevention.


Market Size Forecast & Key Insights

2019
$714M2024
2029
$1.3B2034

Absolute Growth Opportunity = $553M

The Prasugrel Hydrochloride market is projected to grow from $714.2 million in 2024 to $1.27 billion in 2034. This represents a CAGR of 5.9%, reflecting rising demand across Cardiovascular Treatments, Dual Antiplatelet Therapy and Percutaneous Coronary Intervention.

The Prasugrel Hydrochloride market is set to add $553 million between 2024 and 2034, with manufacturer targeting Outpatient Clinics & Home Healthcare End User projected to gain a larger market share.

With Rising incidence of cardiovascular diseases, and Advancements in drug delivery methods, Prasugrel Hydrochloride market to expand 77% between 2024 and 2034.

Opportunities in the Prasugrel Hydrochloride Market

Strategic Collaborations and Partnerships

There is a significant for growth in the Prasugrel Hydrochloride industry through strategic partnerships and collaborations.

Market Potential in Developing Countries and Technological Innovations in Drug Delivery Mechanisms

Emerging markets present a significant for Prasugrel Hydrochloride expansion. Countries such as India, China, and Brazil, exhibit high rates of heart-related illnesses, providing a vast patient pool for the application of Prasugrel Hydrochloride. These markets, while sizable, are still underpenetrated, hence providing a lucrative potential of growth. Furthermore, the improving healthcare infrastructures, coupled with the rising awareness about chronic diseases in these markets, act as catalytic factors for Prasugrel Hydrochloride adoption.

Technological advancements in drug delivery mechanisms offer enormous potential for the productive use of Prasugrel Hydrochloride. Nanotechnology, for instance, is transforming the pharmaceutical industry by enhancing targeted drug delivery, reducing side-effects, and improving patient adherence. By leveraging such technologies, new formulations of Prasugrel Hydrochloride could be developed with enhanced efficacy, thereby escalating its market demand.

Growth Opportunities in North America and Europe

Europe Outlook

The European Prasugrel Hydrochloride market, reflects a varied landscape. In Western Europe, the scenario mirrors North America, with high competition, patient awareness, and healthcare expenditure. Novel drug delivery systems using Prasugrel Hydrochloride could inspire growth in this saturated market. In contrast, Eastern Europe presents untapped potential. Despite the lower healthcare budget, the increasing burden of cardiovascular diseases presents a significant market opportunity for Prasugrel Hydrochloride.

North America Outlook

In North America, Prasugrel Hydrochloride market is in a phase of maturity, with high proclivity for advanced therapies in cardiovascular disorders dictating the demand. The market is primarily driven by a robust presence of pharmaceutical heavyweights, high consumer awareness, and significant healthcare expenditure. However, competition is fierce. Big players such as Eli Lilly boast its Prasugrel Hydrochloride product, Effient, leaving limited room for new entrants. Furthermore, the rise of generics may challenge the brand-name Prasugrel Hydrochloride treatments. Growth opportunities lie in the advent of personalized medicine, where more efficacious use of Prasugrel Hydrochloride for patient-specific needs could foster market expansion. The regions empirical emphasis on clinical evidence could also enhance Prasugrel Hydrochlorides positioning for off-label uses.

North America Outlook

In North America, Prasugrel Hydrochloride market is in a phase of maturity, with high proclivity for advanced therapies in cardiovascular disorders dictating the demand. The market is primarily driven by a robust presence of pharmaceutical heavyweights, high consumer awareness, and significant healthcare expenditure. However, competition is fierce. Big players such as Eli Lilly boast its Prasugrel Hydrochloride product, Effient, leaving limited room for new entrants. Furthermore, the rise of generics may challenge the brand-name Prasugrel Hydrochloride treatments. Growth opportunities lie in the advent of personalized medicine, where more efficacious use of Prasugrel Hydrochloride for patient-specific needs could foster market expansion. The regions empirical emphasis on clinical evidence could also enhance Prasugrel Hydrochlorides positioning for off-label uses.

Europe Outlook

The European Prasugrel Hydrochloride market, reflects a varied landscape. In Western Europe, the scenario mirrors North America, with high competition, patient awareness, and healthcare expenditure. Novel drug delivery systems using Prasugrel Hydrochloride could inspire growth in this saturated market. In contrast, Eastern Europe presents untapped potential. Despite the lower healthcare budget, the increasing burden of cardiovascular diseases presents a significant market opportunity for Prasugrel Hydrochloride.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, China are expected to grow at 3.8% to 5.7% CAGR

2

Emerging Markets : Brazil, South Africa, United Arab Emirates are expected to grow at 6.8% to 8.1% CAGR

Market Analysis Chart

The market for Prasugrel Hydrochloride, an integral component in the treatment of acute coronary syndromes, remains competitive and dynamic. Theindustry'sdriving causes encompass an increasing demand-driven by trends in cardiac health and a surge in acute coronary syndromes. As an antiplatelet medication, Prasugrel Hydrochloride plays a pivotal role in this domain, thus promoting its substantial market growth. Nonetheless, the market growth isnt entirely uninhibited.

Recent Developments and Technological Advancement

December 2024

Leading pharmaceutical manufacturer, Pfizer Inc., announced its expansion plans to amplify the production of Prasugrel Hydrochloride, effectively addressing the growing demand in the global cardiovascular therapeutics market.

October 2024

Johnson & Johnson launched a novel blood thinner drug, integrating Prasugrel Hydrochloride as the core active ingredient, receiving positive feedback from medical professionals for its efficacy in preventing strokes and heart attacks.

July 2024

Roche Diagnostics introduced a predictive analytics tool for Prasugrel Hydrochloride, aiding clinicians to determine the optimal patient dosage, thus enhancing personalized medicine approaches in the landscape of anticoagulant treatments.

Prasugrel Hydrochloride has witnessed significant advancements in the recent years, particularly in the realm of cardiovascular treatments. This compound, primarily utilized as an antiplatelet medication, has carved its niche in an increasingly competitive medical marketplace.

Impact of Industry Transitions on the Prasugrel Hydrochloride Market

As a core segment of the Pharmaceutical industry, the Prasugrel Hydrochloride market develops in line with broader industry shifts. Over recent years, transitions such as Evolution of Therapeutic Methods and Advancement in Drug Delivery Systems have redefined priorities across the Pharmaceutical sector, influencing how the Prasugrel Hydrochloride market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Evolution of Therapeutic Methods:

The pharmaceutical industry has seen a significant shift towards personalized medication for chronic diseases, a trend that has been mirrored in the prasugrel hydrochloride market. Prasugrel hydrochloride, primarily used to prevent clotting in individuals with cardiac conditions, has been at the forefront of this transition. The emphasis has moved from generalized treatment protocols to tailoring doses and therapeutics to the patients unique medical profile. For instance, dosages of prasugrel hydrochloride, are often adjusted based on the patients weight, other medications, and a host of individual factors. This shift towards precision medicine has had a positive impact on patient outcomes, increasing the efficacy of prasugrel hydrochloride in mitigating the risk of cardiovascular events post stentimplantation.

2

Advancement in Drug Delivery Systems:

The prasugrel hydrochloride market has not only been a stranger to the wave of innovations and breakthroughs that have redefined drug delivery systems in recent years.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Prasugrel Hydrochloride market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Incidence of Cardiovascular Diseases

The surge in the occurrence of cardiovascular diseases across the globe is also significantly driving the growth of the Prasugrel Hydrochloride market. As it is also an antiplatelet drug, it is also frequently prescribed for patients suffering from CVDs for preventing blood clots, reducing the chances of heart attacks and strokes. This growing incidence of cardiovascular diseases globally, has also intensified the demand for effective treatments and preventive measures, fueling the need for drugs like Prasugrel Hydrochloride, thus propelling market growth significantly.
Technological advancements in drug delivery methods have also accelerated the development of innovative medication, encouraging the utilization of Prasugrel Hydrochloride. The development of advanced drug delivery systems has also not only improved the efficiency of drugs but has also also increased patient compliance, thereby spurring the demand for Prasugrel Hydrochloride in the pharmaceutical sector. The continuous invention and implementation of advanced drug delivery technologies underline the potential for substantial market growth.

Restraint: Regulatory Hurdles

The advancement and development of Prasugrel Hydrochloride face complex regulatory hurdles. These include stringent rules for the approval and production of drug components, which require manufacturers to operate at very high standards of precision and integrity. The necessity to conduct comprehensive clinical trials that ascertain the drugs efficacy and safety for consumption inflicts heavy cost burdens. Such complexities potentially decrease the market availability and accessibility of Prasugrel Hydrochloride, deterring potential new entrants and constricting market growth.

Challenge: High Cost of Production

Prasugrel Hydrochloride requires a unique blend of technology and expertise for its production, often necessitating significant financial investments. From its procurement to its final pharmaceutical formulation, each step involves granular precision, state-of-art chemical processes, and stringent quality checks, which are financially demanding.

Supply Chain Landscape

Raw Material Suppliers

Sigma-Aldrich

BASF

Intermediate Manufacturers

Sanofi

Dr. Reddy's Laboratories

API Producers
Cardinal Health / Alvogen
Final Formulation & Packaging
Eli Lilly and Company / Daiichi Sankyo
Raw Material Suppliers

Sigma-Aldrich

BASF

Intermediate Manufacturers

Sanofi

Dr. Reddy's Laboratories

API Producers

Cardinal Health

Alvogen

Final Formulation & Packaging

Eli Lilly and Company

Daiichi Sankyo

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Antiplatelet Therapy
Medical & Healthcare
Eli Lilly and Company
Emphasizing on research and development (R&D) to introduce effective and innovative solutions
Treatment of Acute Coronary Syndromes
Pharmaceuticals
Daiichi Sankyo Company
Focusing on collaborative partnerships for global reach and advanced solutions
Management of Percutaneous Coronary Intervention
Biotech & Pharmaceuticals
Ube Industries Ltd.
Adopting continuous improvements and high manufacturing standards to ensure quality and safety

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Prasugrel Hydrochloride market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Prasugrel Hydrochloride in Dual Antiplatelet Therapy, Percutaneous Coronary Intervention and Cardiovascular Treatments

Dual Antiplatelet Therapy

Prasugrel Hydrochloride is often part of a dual antiplatelet therapy regime, usually paired with aspirin. This combination has shown advantageous effects in preventing stent thrombosis. Key players like AstraZeneca and Novartis have explored this application, creating comprehensive healthcare solutions for patients with acute coronary syndrome.

Percutaneous Coronary Intervention

Another common use of Prasugrel Hydrochloride is in percutaneous coronary intervention . This technique is instrumental in treating patients with unstable angina or myocardial infarction. Use of Prasugrel Hydrochloride in this regard helps to inhibit platelet activation and aggregation, which are key in managing these conditions. Top firms such as Sanofi and Boehringer Ingelheim have integrated this usage into their product portfolios.

Cardiovascular Treatments

Prasugrel Hydrochloride is highly employed in cardiovascular treatments, particularly in preventing clotting after a heart attack or stroke. It is a core component in antiplatelet medication, making it a valuable asset in reducing risk of future cardiac events. Significant players in this field who utilize Prasugrel Hydrochloride include giants like Eli Lilly and Daiichi Sankyo, who have capitalized on this application due to its proven efficacy and reliability.

Prasugrel Hydrochloride vs. Substitutes:
Performance and Positioning Analysis

Prasugrel Hydrochloride, unlike its alternatives such as clopidogrel, exhibits a faster and stronger platelet inhibition. In the medical industry, it proves uniquely positioned due to the potential growth in heart disease treatments. These Alternatives specially Eptifibatide has experienced a rapid growth as detailed in our latest report.

Prasugrel Hydrochloride
  • Clopidogrel Bisulfate /
  • Ticagrelor /
  • Eptifibatide
    Efficient platelet inhibition, Lower risk of recurrent cardiovascular events
    Higher risk of bleeding, Not suitable for patients with a history of stroke or transient ischemic attack
    Effective in platelet aggregation inhibition, lower resistance rates
    Higher risk of bleeding complications, not recommended for patients with history of stroke

Prasugrel Hydrochloride vs. Substitutes:
Performance and Positioning Analysis

Prasugrel Hydrochloride

  • Efficient platelet inhibition, Lower risk of recurrent cardiovascular events
  • Higher risk of bleeding, Not suitable for patients with a history of stroke or transient ischemic attack

Clopidogrel Bisulfate / Ticagrelor / Eptifibatide

  • Effective in platelet aggregation inhibition, lower resistance rates
  • Higher risk of bleeding complications, not recommended for patients with history of stroke

Prasugrel Hydrochloride, unlike its alternatives such as clopidogrel, exhibits a faster and stronger platelet inhibition. In the medical industry, it proves uniquely positioned due to the potential growth in heart disease treatments. These Alternatives specially Eptifibatide has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Prasugrel Hydrochloride market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Prasugrel Hydrochloride across Hospitals, Outpatient Clinics, and Home Healthcare Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Eli Lilly and Company, Tokyo Chemical Industry Co. Ltd., and Alchem International by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Intermediate Manufacturers, and API Producers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Prasugrel Hydrochloride segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Sigma-Aldrich, BASF), Intermediate Manufacturers (Sanofi, Dr. Reddy's Laboratories), and API Producers. Our parallel substitute analysis examines Clopidogrel Bisulfate, Ticagrelor, and Eptifibatide, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Eli Lilly and Company, Tokyo Chemical Industry Co. Ltd., and Alchem International, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Prasugrel Hydrochloride market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Prasugrel Hydrochloride Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 756 million
Revenue Forecast in 2034USD 1.27 billion
Growth RateCAGR of 5.9% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024714 million
Growth OpportunityUSD 553 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024714 million USD
Market Size 2027848 million USD
Market Size 2029951 million USD
Market Size 20301.01 billion USD
Market Size 20341.27 billion USD
Market Size 20351.34 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredApplication, End User, Manufacturing Process, Distribution Channel, Regulations
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledEli Lilly and Company, Tokyo Chemical Industry Co. Ltd., Alchem International, Strides Pharma Science Limited, Dr. Reddy's Laboratories, Asahi Kasei Corporation, Synthokem Labs, Aurobindo Pharma, Mylan N.V., LGM Pharma, MSN Laboratories and Sun Pharmaceutical Industries Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Prasugrel Hydrochloride Market Size, Opportunities & Strategic Insights, by Application

4.1Stroke Prevention
4.2Post-Traumatic Injuries
4.3Drug Combination Therapies
4.4Others
Chapter 5

Prasugrel Hydrochloride Market Size, Opportunities & Strategic Insights, by End User

5.1Hospitals
5.2Outpatient Clinics
5.3Home Healthcare
5.4Others
Chapter 6

Prasugrel Hydrochloride Market Size, Opportunities & Strategic Insights, by Manufacturing Process

6.1Synthetic Methods
6.2Biosynthesis
Chapter 7

Prasugrel Hydrochloride Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Pharmacy Stores
7.2Online Pharmacies
7.3Institutional Sales
Chapter 8

Prasugrel Hydrochloride Market Size, Opportunities & Strategic Insights, by Regulations

8.1FDA Approved
8.2Non-FDA Approved
Chapter 9

Prasugrel Hydrochloride Market, by Region

9.1North America Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Prasugrel Hydrochloride Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Eli Lilly and Company
10.2.2Tokyo Chemical Industry Co. Ltd.
10.2.3Alchem International
10.2.4Strides Pharma Science Limited
10.2.5Dr. Reddy's Laboratories
10.2.6Asahi Kasei Corporation
10.2.7Synthokem Labs
10.2.8Aurobindo Pharma
10.2.9Mylan N.V.
10.2.10LGM Pharma
10.2.11MSN Laboratories
10.2.12Sun Pharmaceutical Industries Ltd.